Characterisation of <scp>HER</scp>2‐Driven Morphometric Signature in Breast Cancer and Prediction of Risk of Recurrence
Our findings underscore the strong prognostic and predictive correlation between HER2 histo-morphometric features and response to targeted anti-HER2 therapy.
Authors
- Asmaa Ibrahim (ORCID: https://orcid.org/0000-0002-0330-9949)
- Michael S. Toss (ORCID: https://orcid.org/0000-0002-9077-3984)
- Emad A. Rakha (ORCID: https://orcid.org/0000-0002-5009-5525)
- N Atallah (ORCID: https://orcid.org/0000-0001-6845-5608)
- Shorouk Makhlouf (ORCID: https://orcid.org/0000-0003-3889-9659)
- Nigel P. Mongan (ORCID: https://orcid.org/0000-0001-5438-1126)
- Mohamed Nabil
Institutions
- Suez Canal University (EG)
- Nottingham University Hospitals NHS Trust (GB)
- University of Nottingham (GB)
- Cornell University (US)
- Royal Hallamshire Hospital (GB)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- Weill Cornell Medicine (US)
- Hamad Medical Corporation (QA)
- Menoufia University (EG)
- Assiut University (EG)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/cam4.70852
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00